Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.41 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.41 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14521457 | 0.94 | TSHR (0.54) | TSHREPHX2LMNACYP2D6CYP2C9 | |
| SCHEMBL12017878 | 0.86 | TSHR (0.50) | TSHREPHX2LMNACYP2D6CYP2C9 | |
| SCHEMBL10422914 | 0.84 | EPHX2 (0.48) | TSHREPHX2LMNAALDH1A1ALDH1A2 | |
| SCHEMBL18768870 | 0.84 | TSHR (0.52) | TSHREPHX2LMNAALDH1A1RECQL | |
| SCHEMBL10520237 | 0.84 | EPHX2 (0.48) | TSHREPHX2LMNAALDH1A1ALDH1A2 | |
| SCHEMBL861034 | 0.83 | KMT2A (0.57) | TSHRCYP2D6CYP2C9CYP2C19KMT2A | |
| SCHEMBL23839910 | 0.81 | ALDH1A1 (0.58) | CYP2D6CYP2C9CYP2C19KMT2AALDH1A1 | |
| SCHEMBL17777241 | 0.81 | ALDH1A1 (0.58) | CYP2D6CYP2C9CYP2C19KMT2AALDH1A1 | |
| SCHEMBL23188735 | 0.81 | ALDH1A1 (0.58) | CYP2D6CYP2C9CYP2C19KMT2AALDH1A1 | |
| SCHEMBL9830431 | 0.80 | ADRA1A (0.59) | TSHREPHX2LMNACYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067650-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20200062757-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2020-02-27 | — | — | US | disclosed |
| US-10434186-B2 | Functionalized linear ligands and complexes thereof | LUMIPHORE, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-10239878-B2 | Macrocyclic ligands with pendant chelating moieties and complexes thereof | LUMIPHORE, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180194766-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20170360956-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2017-12-21 | — | — | US | disclosed |
| WO-2016106241-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | LUMIPHORE, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360956-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | CLTB, CLTA, EPCAM | TSHR 804/4885EPHX2 3366/4885LMNA 1626/4885 |
| US-20200062757-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | TFRC, CLTC, SLC39A3 | TSHR 477/4885EPHX2 4151/4885LMNA 3330/4885 |
| US-10434186-B2 | Functionalized linear ligands and complexes thereof | CLTB, CLTA, EPCAM | TSHR 804/4885EPHX2 3366/4885LMNA 1626/4885 |
| US-20240067650-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | TFRC, CLTC, SLC39A3 | TSHR 477/4885EPHX2 4151/4885LMNA 3330/4885 |
| US-20180194766-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | TFRC, CLTC, SLC39A3 | TSHR 477/4885EPHX2 4151/4885LMNA 3330/4885 |
| US-10239878-B2 | Macrocyclic ligands with pendant chelating moieties and complexes thereof | TFRC, CLTC, SLC39A3 | TSHR 477/4885EPHX2 4151/4885LMNA 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.